Free Trial
NASDAQ:KLRS

Kalaris Therapeutics (KLRS) Stock Price, News & Analysis

Kalaris Therapeutics logo
$3.56 +0.48 (+15.58%)
As of 04:00 PM Eastern

About Kalaris Therapeutics Stock (NASDAQ:KLRS)

Key Stats

Today's Range
$3.08
$3.96
50-Day Range
$2.27
$3.08
52-Week Range
$2.14
$24.15
Volume
328,105 shs
Average Volume
45,653 shs
Market Capitalization
$66.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Hold

Company Overview

Kalaris Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
10th Percentile Overall Score

KLRS MarketRank™: 

Kalaris Therapeutics scored higher than 10% of companies evaluated by MarketBeat, and ranked 916th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kalaris Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Kalaris Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Kalaris Therapeutics' stock forecast and price target.
  • Price to Book Value per Share Ratio

    Kalaris Therapeutics has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for KLRS.
  • Dividend Yield

    Kalaris Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Kalaris Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for KLRS.
  • News Sentiment

    Kalaris Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Kalaris Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for KLRS on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Kalaris Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Kalaris Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    74.99% of the stock of Kalaris Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    66.05% of the stock of Kalaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Kalaris Therapeutics' insider trading history.
Receive KLRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kalaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KLRS Stock News Headlines

Leerink Partnrs Issues Negative Forecast for KLRS Earnings
What is William Blair's Forecast for KLRS Q3 Earnings?
A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
See More Headlines

KLRS Stock Analysis - Frequently Asked Questions

Kalaris Therapeutics' stock was trading at $2.79 at the start of the year. Since then, KLRS shares have increased by 27.6% and is now trading at $3.56.

Kalaris Therapeutics Inc. (NASDAQ:KLRS) issued its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.10.

Top institutional investors of Kalaris Therapeutics include Octagon Capital Advisors LP (1.93%), Gilead Sciences Inc. (1.70%) and XTX Topco Ltd (0.13%).

Shares of KLRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/13/2025
Today
8/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KLRS
CIK
1754068
Web
N/A
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

High Price Target
$3.00
Low Price Target
$3.00
Potential Upside/Downside
-15.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$58.77 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-81.02%
Return on Assets
-65.15%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.98
Quick Ratio
11.98

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.84 per share
Price / Book
1.25

Miscellaneous

Outstanding Shares
18,700,000
Free Float
4,677,000
Market Cap
$66.57 million
Optionable
N/A
Beta
0.49
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:KLRS) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners